Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors

Title:Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors

Volume: 18 Issue: 12

Author(s): Anna Campanati, Elisa Molinelli*, Valerio Brisigotti and Annamaria Offidani

Affiliation:

• Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona,Italy

Keywords: Adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, anti-TNFα, efficacy, safety.

Abstract: Background: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored.

Methods: Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)- 12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).

Results: In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and safety of TNFα inhibitors largely used in the management of the cutaneous disease.

Conclusion: Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed anti-TNFα are here discussed in detail.

Cite this article as:

Campanati Anna, Molinelli Elisa*, Brisigotti Valerio and Offidani Annamaria, Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666180209121804